AU2016255034A1 - Methods for treating cancer with a STAT3 pathway inhibitor and kinase inhibitor - Google Patents
Methods for treating cancer with a STAT3 pathway inhibitor and kinase inhibitor Download PDFInfo
- Publication number
- AU2016255034A1 AU2016255034A1 AU2016255034A AU2016255034A AU2016255034A1 AU 2016255034 A1 AU2016255034 A1 AU 2016255034A1 AU 2016255034 A AU2016255034 A AU 2016255034A AU 2016255034 A AU2016255034 A AU 2016255034A AU 2016255034 A1 AU2016255034 A1 AU 2016255034A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cancer
- formula
- foregoing
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153385P | 2015-04-27 | 2015-04-27 | |
| US62/153,385 | 2015-04-27 | ||
| PCT/US2016/029328 WO2016176190A1 (en) | 2015-04-27 | 2016-04-26 | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016255034A1 true AU2016255034A1 (en) | 2017-11-02 |
Family
ID=56081544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016255034A Abandoned AU2016255034A1 (en) | 2015-04-27 | 2016-04-26 | Methods for treating cancer with a STAT3 pathway inhibitor and kinase inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180250261A1 (enExample) |
| EP (1) | EP3288552A1 (enExample) |
| JP (2) | JP2018514557A (enExample) |
| KR (1) | KR20170141716A (enExample) |
| CN (1) | CN107683137A (enExample) |
| AU (1) | AU2016255034A1 (enExample) |
| BR (1) | BR112017022958A2 (enExample) |
| CA (1) | CA2983468A1 (enExample) |
| EA (1) | EA201792320A1 (enExample) |
| HK (1) | HK1252172A1 (enExample) |
| IL (1) | IL255023A0 (enExample) |
| MX (1) | MX2017013816A (enExample) |
| PH (1) | PH12017501882A1 (enExample) |
| SG (1) | SG11201708506QA (enExample) |
| TW (1) | TW201713329A (enExample) |
| WO (1) | WO2016176190A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| WO2018005444A2 (en) * | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| WO2022178957A1 (zh) * | 2021-02-25 | 2022-09-01 | 毕庶壮 | Napabucasin的制药用途 |
| CN116173004A (zh) * | 2021-11-26 | 2023-05-30 | 上海交通大学附属瑞金医院 | 硝呋齐特在制备用于预防或治疗肾上腺皮质癌的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2736177A1 (en) * | 2007-09-06 | 2009-03-12 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| US20160030384A1 (en) * | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
-
2016
- 2016-04-26 KR KR1020177032743A patent/KR20170141716A/ko not_active Withdrawn
- 2016-04-26 SG SG11201708506QA patent/SG11201708506QA/en unknown
- 2016-04-26 EA EA201792320A patent/EA201792320A1/ru unknown
- 2016-04-26 JP JP2017556740A patent/JP2018514557A/ja not_active Withdrawn
- 2016-04-26 EP EP16725260.0A patent/EP3288552A1/en not_active Withdrawn
- 2016-04-26 AU AU2016255034A patent/AU2016255034A1/en not_active Abandoned
- 2016-04-26 HK HK18111573.2A patent/HK1252172A1/zh unknown
- 2016-04-26 US US15/569,236 patent/US20180250261A1/en not_active Abandoned
- 2016-04-26 BR BR112017022958A patent/BR112017022958A2/pt not_active Application Discontinuation
- 2016-04-26 MX MX2017013816A patent/MX2017013816A/es unknown
- 2016-04-26 CN CN201680032224.8A patent/CN107683137A/zh active Pending
- 2016-04-26 WO PCT/US2016/029328 patent/WO2016176190A1/en not_active Ceased
- 2016-04-26 CA CA2983468A patent/CA2983468A1/en not_active Abandoned
- 2016-04-27 TW TW105113235A patent/TW201713329A/zh unknown
-
2017
- 2017-10-15 IL IL255023A patent/IL255023A0/en unknown
- 2017-10-18 PH PH12017501882A patent/PH12017501882A1/en unknown
-
2021
- 2021-05-25 JP JP2021087483A patent/JP2021121629A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201792320A1 (ru) | 2018-02-28 |
| JP2018514557A (ja) | 2018-06-07 |
| JP2021121629A (ja) | 2021-08-26 |
| IL255023A0 (en) | 2017-12-31 |
| BR112017022958A2 (pt) | 2018-07-17 |
| CN107683137A (zh) | 2018-02-09 |
| SG11201708506QA (en) | 2017-11-29 |
| WO2016176190A1 (en) | 2016-11-03 |
| MX2017013816A (es) | 2018-11-12 |
| CA2983468A1 (en) | 2016-11-03 |
| EP3288552A1 (en) | 2018-03-07 |
| PH12017501882A1 (en) | 2018-03-05 |
| KR20170141716A (ko) | 2017-12-26 |
| US20180250261A1 (en) | 2018-09-06 |
| TW201713329A (zh) | 2017-04-16 |
| HK1252172A1 (zh) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180250261A1 (en) | Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
| US20180085341A1 (en) | Methods for treating cancer | |
| US10646464B2 (en) | Methods for treating cancer | |
| US20190231735A1 (en) | Methods for treating cancer | |
| WO2018005444A2 (en) | Methods for treating cancer | |
| US20180098959A1 (en) | Methods for treating cancer | |
| US20250235425A1 (en) | New Combination Solution for Treating Chemotherapy Refractory Cancer | |
| HK40047114A (en) | New combination solution for treating chemotherapy refractory cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |